8,473 reports of this reaction
2.8% of all ADALIMUMAB ADAZ reports
#2 most reported adverse reaction
OFF LABEL USE is the #2 most commonly reported adverse reaction for ADALIMUMAB ADAZ, manufactured by Cordavis Limited. There are 8,473 FDA adverse event reports linking ADALIMUMAB ADAZ to OFF LABEL USE. This represents approximately 2.8% of all 305,491 adverse event reports for this drug.
Patients taking ADALIMUMAB ADAZ who experience off label use should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OFF LABEL USE is a less commonly reported adverse event for ADALIMUMAB ADAZ, but still significant enough to appear in the safety profile.
In addition to off label use, the following adverse reactions have been reported for ADALIMUMAB ADAZ:
The following drugs have also been linked to off label use in FDA adverse event reports:
OFF LABEL USE has been reported as an adverse event in 8,473 FDA reports for ADALIMUMAB ADAZ. This does not prove causation, but indicates an association observed in post-market surveillance data.
OFF LABEL USE accounts for approximately 2.8% of all adverse event reports for ADALIMUMAB ADAZ, making it one of the most commonly reported side effect.
If you experience off label use while taking ADALIMUMAB ADAZ, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.